



Proteomics International

LABORATORIES LTD

ASX Release
24 March 2022

ASX code: PIQ

PromarkerD patent granted in India

- **Proteomics International granted patent for PromarkerD test in India, where the company has a strong existing footprint**
- **India is home to more than 74 million people with diabetes, the second highest in the world**
- **Granted India patent adds to an already strong and existing portfolio of patents and joins those already granted for the USA, Europe, Australia, Brazil, Canada, China, Indonesia, Russia, Singapore and Japan**
- **PromarkerD Intellectual property portfolio now covers 63% of the global population living with diabetes**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces it has been granted a patent in India for PromarkerD, the world's first predictive diagnostic test for diabetic kidney disease.

India is home to more than 74 million people with diabetes, according to the International Diabetes Federation. That number is expected to rise to almost 93 million by 2030s¹. India has the second highest amount of adults living with diabetes in the world, second only to China.

Proteomics International managing director Dr Richard Lipscombe said it was fantastic to secure a patent for India, where the company already has a strong analytical services footprint. *"Proteomics International has strong ties to India, having operated in the country since 2004. We've also taken part in multiple trade visits to India, connecting with the huge Indian biotechnology and pharma sectors."*

The granted India patent complements those already granted in the USA, Europe, Australia, Brazil, Canada, China, Indonesia, Russia, Singapore and Japan. Together, the Company's PromarkerD intellectual property portfolio covers 63% of the world's population living with diabetes.

The International Diabetes Federation estimates there are 537 million adults living with diabetes globally, and one-in-three currently have diabetic kidney disease².

Dr Lipscombe said early detection of a decline in kidney function allows doctors and patients to take preventative action. *"PromarkerD can help prevent the need for renal replacement therapies such as dialysis and kidney transplant, potentially saving global healthcare systems billions of dollars a year."*

The India patent (no. 390245) is titled 'Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions'. It will extend until September 2031.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

¹ International Diabetes Federation Diabetes Atlas 10th edition

² Centers for Disease Control and Prevention. *Chronic Kidney Disease in the United States, 2019*

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

ENDS

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com